Relypsa Initiates Open-Label Phase 2 Clinical Study Of RLY5016 for the management of hyperkalemiaRelypsa, today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical trial of the company’s lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder for the prevention and treatment of hyperkalemia, a serious by elevated by elevated serum potassium levels..
About RLY5016RLY5016 has developed a high capacity non-absorbed oral potassium binder for the management of hyperkalemia in patients with heart failure and chronic kidney disease. In preclinical and clinical studies RLY5016 has been shown to reduce serum potassium levels and was consistently well tolerated in several clinical studies in healthy volunteers and patients.In Japan, Chugai will conduction phase III of clinical trials in rheumatoid arthritis and submission for approval has planned for 2006. Phase of III trials to RA in the countries outside Japan be done in collaboration with Roche for more than 4,000 patients in 20 countries which makes the bag planning in 2007.
Note:improve signs and symptoms . Administration of should be has patients, does not on said swollen lymph node resection indicates limited.